1
TÍTULO: Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group
AUTORES: Aapro, MS; van Wijk, FH; Bolis, G; Chevallier, B; van der Burg, MEL; Poveda, A; de Oliveira, CF; Tumolo, S; di Palumbo, VS; Piccart, M; Franchi, M; Zanaboni, F; Lacave, AJ; Fontanelli, R; Favalli, G; Zola, P; Guastalla, JP; Rosso, R; Marth, C; Nooij, M; Presti, M; Scarabelli, C; Splinter, TAW; Ploch, E; Beex, LVA; Huinink, WT; Forni, M; Melpignano, M; Blake, P; Kerbrat, P; Mendiola, C; Cervantes, A; Goupil, A; Harper, PG; Madronal, C; Namer, M; Scarfone, G; Stoot, JEGM; Teodorovic, I; Coens, C; Vergote, I; Vermorken, JB; ...Mais
PUBLICAÇÃO: 2003, FONTE: ANNALS OF ONCOLOGY, VOLUME: 14, NÚMERO: 3
INDEXADO EM: Scopus WOS CrossRef
2
TÍTULO: Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix: An EORTC Gynecological Cancer Cooperative Group study
AUTORES: Vermorken, JB; Zanetta, G; Oliveira, CFD; van der Burg, MEL; Lacave, AJ; Teodorovic, I; Boes, GH; Colombo, N;
PUBLICAÇÃO: 2001, FONTE: ANNALS OF ONCOLOGY, VOLUME: 12, NÚMERO: 7
INDEXADO EM: WOS CrossRef: 26